Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks

The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.